Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Visceral pain is defined as an internal pain caused due to inflammation of internal organs such as uterus, stomach, rectum, and bladder. This inflammation arises owing to several factors such as infection, trauma, or any injury outside or inside of the internal organs. The visceral pain caused by this varies in strength from being sharp, constant or sometimes very deep pain such as squeezing out of the body.

The governments of various countries and pharmaceutical companies are increasingly investing in research & development to develop novel drugs, which is expected to propel the global visceral pain treatment market growth during the forecast period. Moreover, the increasing prevalence of irritable bowel syndrome is also projected to boost the market growth. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD) in 2016, up to 10% to 15% of adults all over the world are affected by irritable bowel syndrome (IBS) every year.

Visceral Pain Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

Visceral pain treatment market size is hugely affected due to the outbreak of COVID-19 across the globe. In clinical trials, the possibility of visceral abdominal pain has major implications during the COVID-19 pandemic. When COVID-19 patients report severe abdominal pain, the visceral infarction should be considered in disparity diagnosis and should be taken into account in imaging diagnostics and laboratory workups. It is challenging for key players and researchers to perform clinical trials during the pandemic. On the contrary, several market players and governments are investing in R&D activities for the development of novel drugs for visceral pain.

The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.

The global visceral pain treatment market is estimated to be valued at US$ 11,673.8 million in 2020 and is expected to rise at a CAGR of 5.2% during the forecast period (2020-2027).

Figure 1: Global Visceral Pain Treatment Market Share (%) Analysis, By Indication, 2020

Visceral Pain Treatment  | Coherent Market Insights

An increase in the number of clinical trials, research & development activities, and drug approvals is expected to boost the visceral pain treatment market growth

Key players in the market are highly investing in research & development and performing clinical trials in order to develop novel drugs in the visceral pain treatment market. The drug approvals in the market are estimated to significantly fuel the market growth and create lucrative growth opportunities in the visceral pain treatment market during the forecast period.

For instance, in January 2019, Ironwood Pharmaceuticals Inc. announced the approval of ‘LINZESS’ of strength 72 mcg, 145 mcg, and 290 mcg in China for the treatment of irritable bowel syndrome (IBS) with constipation in adults. Ironwood and AstraZeneca jointly developed and commercialized linaclotide (LINZESS) in China. Ironwood estimated that it will launch the drug by 2020. Such approvals are likely to enhance the availability of drugs in potential markets, which is benefiting growth of the global visceral pain treatment market.

Furthermore, key players in the industry are adopting strategies such as collaborations and joint agreements to strengthen their market position. For instance, in February 2020, the Drugs for Neglected Diseases initiative (DNDi) and Novartis entered into a collaborative license agreement to co-develop ‘LXE408’ as a potential novel treatment for visceral leishmaniasis, which is one of the leading parasitic killers of the world. LXE408 which is a first-in-class compound, was discovered with financial support from Welcome Trust at Novartis.

request-sample

Visceral Pain Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 11,673.8 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.26% 2027 Value Projection: US$ 16,709.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type:
    • Pain modifiers: Tricyclic Anticonvulsant, Tricyclic Antidepressants.
    • Analgesics: Narcotics, NSAID.
    • Others
  • By Indication: Chronic prostatitis, Interstitial cystitis, Crohn’s Disease, Irritable bowel syndrome.
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Channels.
Companies covered:

Addex Therapeutics Ltd., AstraZeneca, Astellas Pharma Inc., Allergan, Chromocell Corporation, Takeda, GIcare Pharma Inc., Abbvie, Grunenthal GmbH, Johnson & Johnson, Neurim Pharmaceuticals Ltd, and Medestea Research & Production S.p.A.

Growth Drivers:
  • Increasing focus of governments and pharmaceutical companies on research & development
  • Increasing prevalence of irritable bowel syndrome and Crohn’s disease
Restraints & Challenges:
  • Lack of specific treatment for visceral pain

Global Visceral Pain Treatment Market - Restraints

However, lack of specific treatment for visceral pain such as irritable bowel and Crohn’s disease is a major factor, which is expected to hinder growth of the visceral pain treatment market. Moreover, competition amongst the key industry players regarding the development of novel drugs for visceral pain is expected to be a major reason that is likely to restrict the market growth.

Moreover, the high cost of drugs is also expected to be a major threat to growth of the visceral pain treatment market during the forecast period.

Global Visceral Pain Treatment Market – Regional Analysis

North America accounted for majority of share in the visceral pain treatment market in 2019 and is expected to subjugate the industry during the forecast period. This dominance is majorly owing to rising focus of pharmaceutical companies on R&D and joint ventures to develop novel drugs for visceral pain. For instance, in March 2018, Arena Pharmaceuticals presented preclinical data and phase 1 data on APD371 for development of pain treatment related to Crohn’s disease at the APS (American Pain Society) Annual Scientific Summit at San Diego. APD371 or Olorinab is an oral, highly-selective, peripherally acting discovered investigational drug for the visceral pain treatment associated with gastrointestinal disorders.

Moreover, the rising prevalence of irritable bowel syndrome and Crohn’s disease is projected to boost growth of the regional market over the forecast period. For instance, according to the estimations published in the Gastroenterology & Hepatology Journal (G&H) in 2016, Crohn’s disease is one of the most common indications of visceral pain and its prevalence in the North America region is between 400 and 600 cases per 100,000 people. According to the Centers for Disease Control and Prevention (CDC), around 3 million people were diagnosed with irritable bowel disease (IBD) such as ulcerative colitis or Crohn’s disease in 2015.

Furthermore, Asia Pacific region is projected to grow at the fastest pace during the forecast period, owing to increasing investments by pharma companies and governments initiatives visceral pain treatment. For instance, companies such as Glenmark Pharmaceuticals, Takeda Pharmaceutical Company, and others offer visceral pain products and treatment in the Asia Pacific region. Moreover, government authorities such as the government of Australia are focused on increasing awareness about visceral pain and its treatment.

Figure 2: Global Visceral Pain Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Visceral Pain Treatment  | Coherent Market Insights

Global Visceral Pain Treatment Market - Competitive Landscape

Key players operating in the visceral pain treatment market include Addex Therapeutics Ltd., AstraZeneca, Astellas Pharma Inc., Allergan, Chromocell Corporation, Takeda, GIcare Pharma Inc., Abbvie, Grunenthal GmbH, Johnson & Johnson, Neurim Pharmaceuticals Ltd, and Medestea Research & Production S.p.A.

Visceral pain is defined as the pain that results from the nociceptors activation of the pelvic, thoracic or abdominal bowels (organs). The visceral structures are highly sensitive to stretch (distension), inflammation, and ischemia, but moderately insensitive to other stimuli that usually evoke pain such as burning or cutting. The symptoms of visceral pain are vomiting, nausea, changes in vital signs, and emotional manifestations. Pregabalin or gabapentin are some of the medications used for visceral pain treatment.

Market Dynamics

The ongoing research and development by pharmaceutical companies and increasing investments by many governments are expected to propel the visceral pain treatment market growth over the forecast period. For instance, in February 2020, DNDi (Drugs for Neglected Types initiative) and Novartis entered into a joint license agreement to co-develop a potential new treatment for visceral leishmaniasis. Furthermore, the rising prevalence of irritable bowel syndrome (IBS) across the globe is likely to drive the market growth. For instance, in 2016, according to the IFFGD (International Foundation for Gastrointestinal Disorders), around 10 to 15 per cent of the adult population across the globe are affected by IBS each year.

Moreover, key players in this market are highly investing in research and development to develop, create, and commercialize novel drugs for visceral pain, which will create growth opportunities in the global visceral pain treatment market over the forecast period. However, the lack of specific treatment for visceral pain such as Crohn’s disease and irritable bowel syndrome is expected to restrict the market growth in the near future.

Key features of the study:

  • This report provides in-depth analysis of the global visceral pain treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global visceral pain treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study are Addex Therapeutics Ltd., AstraZeneca, Astellas Pharma Inc., Allergan, Chromocell Corporation, Takeda, GIcare Pharma Inc., Abbvie, Grunenthal GmbH, Johnson & Johnson, Neurim Pharmaceuticals Ltd, and Medestea Research & Production S.p.A.
  • Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global visceral pain treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for visceral pain treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Visceral Pain Treatment Market, By Drug Type:
    • Pain modifiers
      • Tricyclic Anticonvulsant
      • Tricyclic Antidepressants
    • Analgesics
      • Narcotics
      • NSAID
    • Others
  • Global Visceral Pain Treatment Market, By Indication:
    • Irritable bowel syndrome
    • Chronic prostatitis
    • Interstitial cystitis
    • Crohn’s Disease
  • Global Visceral Pain Treatment Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channels
  • Global Visceral Pain Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Pain modifiers
          • Tricyclic Anticonvulsant
          • Tricyclic Antidepressants
        • Analgesics
          • Narcotics
          • NSAID
        • Others
      • By Indication:
        • Irritable bowel
        • Chronic prostatitis
        • Interstitial cystitis
        • Crohn’s Disease
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Channels
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Pain modifiers
          • Tricyclic Anticonvulsant
          • Tricyclic Antidepressants
        • Analgesics
          • Narcotics
          • NSAID
        • Others
      • By Indication:
        • Irritable bowel
        • Chronic prostatitis
        • Interstitial cystitis
        • Crohn’s Disease
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Channels
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Pain modifiers
          • Tricyclic Anticonvulsant
          • Tricyclic Antidepressants
        • Analgesics
          • Narcotics
          • NSAID
        • Others
      • By Indication:
        • Irritable bowel
        • Chronic prostatitis
        • Interstitial cystitis
        • Crohn’s Disease
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Channels
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Pain modifiers
          • Tricyclic Anticonvulsant
          • Tricyclic Antidepressants
        • Analgesics
          • Narcotics
          • NSAID
        • Others
      • By Indication:
        • Irritable bowel
        • Chronic prostatitis
        • Interstitial cystitis
        • Crohn’s Disease
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Channels
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Pain modifiers
          • Tricyclic Anticonvulsant
          • Tricyclic Antidepressants
        • Analgesics
          • Narcotics
          • NSAID
        • Others
      • By Indication:
        • Irritable bowel
        • Chronic prostatitis
        • Interstitial cystitis
        • Crohn’s Disease
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Channels
    • Africa
      • By Country/Region:
        • South Africa
        • North Africa
        • Central Africa
      • By Drug Type:
        • Pain modifiers
          • Tricyclic Anticonvulsant
          • Tricyclic Antidepressants
        • Analgesics
          • Narcotics
          • NSAID
        • Others
      • By Indication:
        • Irritable bowel
        • Chronic prostatitis
        • Interstitial cystitis
        • Crohn’s Disease
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Channels

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Advancements in Visceral Pain Treatment
    • Key Developments
    • Acquisition, Collaborations & Partnerships
    • Epidemiology
  4. Global Visceral Pain Treatment Market, Impact of Coronavirus (Covid-19) Pandemic
    • Pre-COVID situation
    • Post-COVID demand
    • Need for Visceral Pain Treatment
  5. Global Visceral Pain Treatment Market, By Drug Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pain modifiers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • Pain Modifiers
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Tricyclic Anticonvulsant
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Tricyclic Antidepressants
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • Narcotics
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • NSAID
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Visceral Pain Treatment Market, By Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Irritable bowel syndrome
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Chronic prostatitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Interstitial cystitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Crohn's Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Visceral Pain Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Channels
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Visceral Pain Treatment Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, By Region, 2017 –2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • Addex Therapeutics Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Allergan
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Chromocell Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GIcare Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abbvie
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Grunenthal GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Neurim Pharmaceuticals Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Medestea Research & Production S.p.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 27 market data tables and 31 figures on "Global Visceral Pain Treatment Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the visceral pain treatment market is expected to be 5.26% during the forecast period (2020-2027).
The value of the global market for the visceral pain treatment is estimated to be valued at US$ 11,673.8 million in 2020.
The prominent players in visceral pain treatment market across the globe are Addex Therapeutics Ltd., AstraZeneca, Astellas Pharma Inc., Allergan, Chromocell Corporation, Takeda, GIcare Pharma Inc., Abbvie, Grunenthal GmbH, Johnson & Johnson, Neurim Pharmaceuticals Ltd, and Medestea Research & Production S.p.A.
The visceral pain treatment market is expected to be valued at US$ 16,709.8 million in 2027.
The major region in the visceral pain treatment market is North America.
Increasing focus of governments and pharmaceutical companies on research & development is a major factor driving growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner